Adage Capital Partners Gp, L.L.C. Sage Therapeutics, Inc. Transaction History

Adage Capital Partners Gp, L.L.C.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$70.65 - $96.76 $31.2 Million - $42.8 Million	-442,000 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$58.41 - $89.06 $29.2 Million - $44.5 Million	-500,000 Reduced 53.08%	442,000 $38.2 Million
Q3 2020 Nov 16, 2020	BUY	$41.13 - $62.45 $38.7 Million - $58.8 Million	942,000 New	942,000 $57.6 Million
Q1 2020 May 15, 2020	SELL	$26.15 - $77.24 $1.31 Million - $3.86 Million	-50,000 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$60.18 - $154.77 $1.81 Million - $4.64 Million	30,000 Added 150.0%	50,000 $3.61 Million
Q1 2019 May 15, 2019	BUY	$89.33 - $163.65 $1.79 Million - $3.27 Million	20,000 New	20,000 $3.18 Million
Q1 2018 May 15, 2018	SELL	$152.15 - $192.33 $20.2 Million - $25.6 Million	-133,000 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$60.72 - $167.34 $8.08 Million - $22.3 Million	133,000	133,000 $21.9 Million

198

46.5M

402K

209K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $323M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.